BioDelivery Sciences International (BDSI) announced that the USPTO has granted BDSI's patent which extends the patent protection for BioErodible MucoAdhesive (BEMA) products, BEMA Buprenorphine and BEMA Buprenorphine/Naloxone, by seven years to 2027.
The company now confirms that the $15m milestone associated with its licensing and development agreement with Endo Pharmaceuticals for BEMA Buprenorphine is payable.
With this the total milestone payments received thus far becomes $45m, the company said.
BDSI is a specialty pharmaceutical company that is leveraging its novel and proprietary patented drug delivery technologies to develop and commercialize, either on its own or in partnerships with third parties, new applications of proven therapeutics.
